Status:

RECRUITING

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Lead Sponsor:

argenx

Conditions:

Immune Thrombocytopenia (ITP)

ITP - Immune Thrombocytopenia

Eligibility:

All Genders

12-17 years

Phase:

PHASE2

PHASE3

Brief Summary

The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP). The study consists ...

Eligibility Criteria

Inclusion

  • Is aged 12 to less than 18 years when completing the informed consent process
  • Has a documented duration of primary ITP of more than 12 months on the date the informed consent process is complete
  • Has documented prior ITP treatment with at least 1 of the following treatments: corticosteroids, IVIg, anti-D immunoglobulin, thrombopoietin receptor agonist (TPO-RAs), or rituximab.
  • Has documented prior response, defined as 1 platelet count of ≥50 × 10\^9/L to at least 1 of the following ITP treatments: prednisone, other or nonspecified corticosteroids, IVIg, or anti-D immunoglobulin
  • Has documented insufficient response to a prior ITP treatment with corticosteroids, IVIg, anti-D immunoglobulin, TPO-RAs, rituximab, or splenectomy
  • Has documented mean platelet count of less than 30 x10\^9/L

Exclusion

  • Secondary ITP according to the following definition by the International Working Group (IWG): all forms of immune-mediated thrombocytopenia except primary ITP
  • Nonimmune thrombocytopenia
  • ITP-associated critical or severe bleeding
  • History of hereditary thrombocytopenia

Key Trial Info

Start Date :

October 20 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2030

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT07194850

Start Date

October 20 2025

End Date

October 1 2030

Last Update

January 8 2026

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Institutul Clinic Fundeni

Bucharest, Romania, 022328

2

Hospital Universitari Vall d'Hebron

Barcelona, Spain, 08035

3

Hospital Sant Joan de Deu Barcelona

Esplugues de Llobregat, Spain, 08950

4

Hospital Infantil Universitario Nino Jesus (HIUNJS)

Madrid, Spain, 28009

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) | DecenTrialz